Navigating Treatment Options in PAH

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Making Decisions With Your Osteoarthritis Patients
Risk Stratification in PAH: What Do the Latest Data Suggest?
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
Setting the Stage – PAH Therapy Trials Current PAH Pharmacotherapies.
Glaucoma Progression.
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
UNDERSTANDING RISK STRATIFICATION IN PAH:
MANAGING GLAUCOMA:.
The Latest Data on Oral Prostacyclin Therapy in PAH
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
All About PAH:.
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Tailoring Hemophilia Prophylaxis Therapy
PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence
Improving Risk Assessment and Early Diagnosis in PAH
Updates in Pulmonary Arterial Hypertension
Improving Management of Type 2 Diabetes in Hispanic/Latino Patients
WHO Clinical Classification of PH Complex Cases in PH.
Selected Highlights of the Latest Advances in PAH
Forming Effective Individualized Treatment Plans for Patients With Low-Risk MDS.
Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?
Evolving Science of PAH Treatment
Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?
Risk Assessment in PAH.
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Examining the Latest Evidence in PAH
Charting Progress in MS Treatment:
Immunotherapy for cSCC
Poor Response to Initial Therapy for Migraine
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Oral Prostanoids and PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
PAH-Related Morbidity as a Predictor of Mortality
PAH Treatment.
Pulmonary Arterial Hypertension and Connective Tissue Disease
What's New in PAH?.
A Guideline-Based Approach to HCV Care
Insulin in Diabetes Management: Effective Patient Selection Is Key
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Oral Prostacyclin Pathway Agents in PAH
Addressing Unmet Needs in Myelofibrosis
Group 1 PAH: Current Therapies
Incorporating Prostacyclins Into Practice
Challenges in LA SCCHN.
Novel Concepts in the Management of RCC
Improving Adherence to Antiplatelet Therapy After an ACS Event
Perspective on the Multidisciplinary Management of PAH
Live on PAH: Breathing Life Into Patients With PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Saving the Day.
Program Goal. Program Goal Disclaimer Overview.
Optimal Treatment of PAH
Peanut Allergy Immunotherapy
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Transitioning Therapy in PAH: Practical Strategies and Considerations
Incorporating New PAH Treatments Into Clinical Practice
PAH Pathways: What Do the Data Tell Us?”
Pulmonary Arterial Hypertension and Hospitalizations
Merging the Art and Science of Managing nOH in Clinical Practice
What's New in PAH?.
My PAH Patient.
Presentation transcript:

Navigating Treatment Options in PAH

Program Goals

Case Study 1

Case Study 1 (cont)

Case Study 1 (cont)

Risk Stratification

Treatment Goals

SERAPHIN PAH Population

Combination Therapy Options for PAH

1-Year Survival Estimates in the Subsequent Year by Change in REVEAL Score

Case Study 2 Initial Visit December 2015

Case Study 2 Test Results

Treatment Algorithm for PAH

Rationale for Combination Therapy

AMBITION Study Design

AMBITION Results

Concluding Comments

Abbreviations

Abbreviations (cont)

Abbreviations (cont)